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Background: This study was designed to test a new approach to drug treatment of autism spectrum disorders
(ASDs) in the Fragile X (Fmr1) knockout mouse model.
Methods: We used behavioral analysis, mass spectrometry, metabolomics, electron microscopy, and western
analysis to test the hypothesis that the disturbances in social behavior, novelty preference, metabolism, and synapse
structure are treatable with antipurinergic therapy (APT).
Results: Weekly treatment with the purinergic antagonist suramin (20 mg/kg intraperitoneally), started at 9 weeks
of age, restored normal social behavior, and improved metabolism, and brain synaptosomal structure. Abnormalities
in synaptosomal glutamate, endocannabinoid, purinergic, and IP3 receptor expression, complement C1q, TDP43,
and amyloid β precursor protein (APP) were corrected. Comprehensive metabolomic analysis identified 20 biochemical
pathways associated with symptom improvements. Seventeen pathways were shared with human ASD, and 11 were
shared with the maternal immune activation (MIA) model of ASD. These metabolic pathways were previously identified
as functionally related mediators of the evolutionarily conserved cell danger response (CDR).
Conclusions: The data show that antipurinergic therapy improves the multisystem, ASD-like features of both the
environmental MIA, and the genetic Fragile X models. These abnormalities appeared to be traceable to mitochondria
and regulated by purinergic signaling.
Keywords: Autism spectrum disorders, Purinergic signaling, Antipurinergic therapy (APT), Mitochondria,
Metabolism, Metabolomics, Fragile X syndrome, Genetics, Environment, Maternal immune activation (MIA),
Cell danger response (CDR)Background
Autism spectrum disorders (ASDs) now affect 1% to 2%
of children in the United States [1]. Genetic [2-4], envir-
onmental [5,6], and metabolic [7] factors can contribute
to the risk of ASD to different extents in each affected
child. We have previously shown that antipurinergic ther-
apy reverses the behavioral and metabolic abnormalities in* Correspondence: naviaux@ucsd.edu
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unless otherwise stated.the maternal immune activation (MIA) mouse model of
ASD in juveniles [8] and adults [9]. The MIA and Fragile
X models have been considered to be mechanistically
distinct examples of environmental and genetic causes of
ASD, respectively. However, in our MIA study we found
the first of several emerging connections. The Fmr1 pro-
tein (FMRP) was downregulated by 50%, and antipuriner-
gic therapy with suramin restored normal FMRP and
normal behaviors in the MIA model [8]. FMRP is an
mRNA and ribosome [10] binding protein that inhibits
the expression of several key inflammatory proteins and
cytokines, and binds to several DNA repair proteins in-
volved in cell stress and defense [11]. Genetic loss of FMRP
expression leads to Fragile X Syndrome, the most commonl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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knockout is the oldest, and one of the most studied genetic
mouse models used in autism research [13]. In our previous
work we found that disturbances in purine metabolism and
purinergic signaling were robust features and effective tar-
gets for treatment in the environmental MIA mouse model
of autism [8,9]. Interestingly, the first genetic causes of aut-
ism identified were traced to abnormalities in purine and
pyrimidine metabolism [14,15]. These observations led us
to test the role of purinergic signaling in a genetic mouse
model of ASD. We selected the Fragile X model to test the
hypothesis that abnormalities in purinergic signaling might
underlie both the environmental MIA and genetic Fragile
X models.
Suramin is a well-known and well-studied competitive
inhibitor of purinergic signaling [16]. It has been used
medically for the treatment of African sleeping sickness
(trypanosomiasis) since shortly after it was first synthe-
sized in 1916. Its antipurinergic actions were discovered
in 1988, after a search for inhibitors of ATP-mediated
P2X and P2Y signaling [17]. Suramin has many other
actions [18], however, metabolomic studies have shown
that the expression of purinergic receptors is altered [8],
and purine metabolism is the top ranked biochemical
pathway that is changed by treatment in the MIA model
of ASD [9]. We refer to the use of suramin and related
purinergic antagonists as antipurinergic therapy (APT).
In the present work, we tested the hypothesis that APT
will improve behavior, metabolism, and synaptic abnor-
malities in the Fragile X mouse model, even in the face




We evaluated the Fragile X (Fmr1) knockout on the
FVB strain background. It has the genotype: FVB.129P2-
Pde6b+ Tyrc-ch Fmr1tm1Cgr/J (Jackson Stock # 004624).
The Fmr1tm1Cgr allele contains a neomycin resistance
cassette replacing exon 5 that results in a null allele
that makes no FMR mRNA or protein. The control strain
used has the genotype: FVB.129P2-Pde6b+ Tyrc-ch/AntJ
(Jackson Stock # 004828). In contrast to the white coat
color of wild-type FVB mice, these animals had a chin-
chilla (Tyrc-ch) gray coat color. The wild-type Pde6b locus
from the 129P2 ES cells corrects the retinal degeneration
phenotype that produces blindness by 5 weeks of age in
typical FVB mice. The Fmr1 locus is X-linked, so males
are hemizygous and females are homozygous for the
knockout. We also performed metabolomic analysis on
Fmr1 knockout mice on the C57BL/6J (B6) background to
refine our understanding of which metabolic disturbances
were directly related to the Fmr1 knockout, and which
were the result of changes in genetic background. Forthese studies we studied the same Fmr1tm1Cgr knockout
allele bred on the C57BL6/J background. These animals
had the genotype: B6.129P2-Fmr1tm1Cgr/J (Jackson
Stock# 003025). The standard C57BL6/J strain (Jackson
Stock# 000664) was used as a control for the B6 metabolic
studies.Animals, husbandry, and drug treatment
All studies were conducted at the University of California,
San Diego (UCSD) in facilities accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC) under UCSD Institutional
Animal Care and Use Committee (IACUC)-approved ani-
mal subjects protocols, and followed the National Institutes
of Health (NIH) Guidelines for the use of animals in
research. Five-week-old male mice were obtained from
Jackson Laboratories (Bar Harbor, ME), identified by
ear tags, placed in cages of two to four animals, and
maintained on ad libitum Harlan Teklad 8604 mouse
chow (14% fat, 54% carbohydrate, 32% protein) and
water. Animals were housed in a temperature (22°C to
24°C) and humidity (40% to 55%) controlled vivarium
with a 12-h light-dark cycle (lights on at 07:00). No
mice were housed in isolation. Beginning at 9 weeks of
age, animals received weekly injections of either saline
(5 μL/g ip) or suramin (hexasodium salt, 20 mg/kg ip;
Tocris Cat #1472).Behavioral analysis
Behavioral testing began at 13 weeks of age, after 1
month of weekly antipurinergic therapy with suramin.
Mice were tested in social approach, T-maze, locomomtor
activity, marble burying, acoustic startle, and prepulse in-
hibition paradigms as follows. The ages at the time of test-
ing are noted in the figure legends. For a complete
description of the behavioral paradigms see Full Methods
Online. Social Preference and Social Novelty. Social behav-
ior was tested as social preference as previously described
[9], with the addition of a third phase with a second novel
mouse to interrogate social novelty [19]. T-Maze. Novelty
preference was tested as spontaneous alternation behavior
in the T-maze as previously described [9]. Marble Burying.
Marble burying behavior was measured over 30 min by a
modification of methods used by Thomas et al. [20]. Loco-
motor Activity. Locomotor activity, hyperactivity (total
distance traveled), center entries, holepoke exploration,
and vertical investigation (rearing) behaviors were quanti-
fied by automated beam break analysis in the mouse be-
havioral pattern monitor (mBPM) as previously described
[21]. Acoustic Startle and Prepulse Inhibition. Sensitivity
to acoustic startle and prepulse inhibition of the startle
reflex were measured by automated testing in commercial
startle chambers as previously described [22].
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A BAT-12 Microprobe digital thermometer and RET-3
mouse rectal probe (Physitemp Instruments, Clifton, NJ,
USA) were used to obtain rectal core temperatures to a
precision of +/-0.1°C, as previously described [8]. Care
was taken to measure temperatures ≥2 days after cage
bedding changes, and to avoid animal transport stress
immediately prior to measurement in order to avoid
stress-induced hyperthermia [23]. Temperatures were
measured between 09:00 and 12:00 each day.
Synaptosome isolation and ultrastructure
Animals were sacrificed at 25 weeks of age, after receiving
16 weeks of treatment with suramin or saline. Cerebral
samples were collected, homogenized, and synaptosomes
isolated by discontinuous Percoll gradient centrifugation,
drop dialyzed, glutaraldehyde fixed, post-fixed in osmium
tetroxide, embedded, sectioned, and stained with uranyl
acetate for transmission electron microscopy (TEM) as
previously described [8]. Samples from the FVB control
animals (+/- suramin) were not available for study by
either electron microscopy or western analysis. Therefore,
we report only the effects of suramin on the two groups of
Fmr1 knockout animals (KO-saline and KO-suramin).
N = 3 animals/group. Four to six TEM images were col-
lected from each sample. One 5,800× survey image, and
three to five images of informative fields at 34,000× to
64,000× were collected with internal scale bars for dimen-
sional control. Qualitatively representative images were
reported.
Western blot analysis
Twenty micrograms of cerebral synaptosomal protein
was loaded in SDS-polyacrylamide gels (NuPage 4-12%
gradient, Bis-Tris Gels) and transferred to PVDF mem-
branes as previously described [8]. The blots were first
stained with 0.1% Ponceau S in 5% acetic acid for 10
min, washed, scanned, and the transfer efficiency was
quantified by densitometry. Blots were then blocked
with 5% skim milk in tris-buffered saline with 0.1%
Tween 20 (TBST) for 1 h at room temperature with
shaking. Primary antibodies were obtained commercially
as 1 mg/mL stocks (see Additional file 1: Table S1 for
source details). These were diluted 1:500 to 1:10,000 (final
concentrations of 2000 ng/mL to 100 ng/mL; Additional
file 1: Table S1) in 5% BSA or 5% skim milk in TBS with
0.1% Tween 20 and optimized for each target to achieve
signals in the linear range using dilutions (5 to 20 μg/lane)
of cerebral synaptosomes prepared from C57BL/6J control
animals. When monoclonal antibodies to a peptide of the
target protein were used, peptide was pre-incubated with
primary antibody to confirm specificity. When blocking
peptides were not available, signal specificity was deter-
mined by correspondence of the observed band patternand molecular weight to the published or manufacturer
values for each target protein. Only antibodies that
identified specific target bands in cerebral synaptosomes
from age-matched control animals were used. Blots
were probed with the optimized dilution of primary
antibody overnight in the cold room (4°C). Secondary
antibodies conjugated to horseradish peroxidase were
obtained from Pierce (Rockford, IL, USA) diluted
1:5,000 (200 ng/mL) to 1:20,000 (50 ng/mL) in 3% skim
milk-TBST. The blots were probed for 1 h at room
temperature prior to final wash and signal development
by enhanced chemiluminescence (ECL) or SuperSignal
West Femto chemiluminsescent substrate (Thermo,
Cat# 34095), then quantified by densitometry. At least
five animals per group were analyzed. We evaluated
the cerebral synaptosome expression of 54 proteins
(Additional file 1: Table S1).
Metabolomics
Broad spectrum analysis of 673 targeted metabolites
from 60 biochemical pathways was performed as de-
scribed [9], with minor modifications. Samples were ana-
lyzed on an AB SCIEX QTRAP 5500 triple quadrupole
mass spectrometer equipped with a Turbo V electro-
spray ionization (ESI) source, Shimadzu LC-20A UHPLC
system, and a PAL CTC autosampler (AB ACIEX, Fra-
mingham, MA, USA). Whole blood was collected 3 to 4
days after the last weekly dose of suramin (20 mg/kg ip)
or saline (5 μL/g ip), after light anesthesia in an isoflurane
(Med-Vet International, Mettawa, IL, USA, Cat# RXISO-
250) drop jar, into BD Microtainer tubes containing lith-
ium heparin (Becton Dickinson, San Diego, CA, USA,
Ref# 365971) by submandibular vein lancet [24]. Plasma
was separated by centrifugation at 600g × 5 min at 20°C
within 1 h of collection. Fresh lithium-heparin plasma was
transferred to labeled tubes for storage at -80°C for ana-
lysis. Typically 45 μL of plasma was thawed on ice and
transferred to a 1.7 mL Eppendorf tube. A total of 2.5 μL
of a cocktail containing 35 commercial stable isotope in-
ternal standards, and 2.5 μL of 310 stable isotope internal
standards that were custom-synthesized in E. coli and
S. cerevisiae by metabolic labeling with 13C-glucose and
13C-bicarbonate, were added, mixed, and incubated for 10
min at room temperature to permit small molecules and
vitamins in the internal standards to associate with plasma
binding proteins. Macromolecules (protein, DNA, RNA,
and so on) were precipitated by extraction with 4 volumes
(200 μL) of cold (-20°C), acetonitrile:methanol (50:50)
(LCMS grade, Cat# LC015-2.5 and GC230-4, Burdick &
Jackson, Honeywell), vortexed vigorously, and incubated
on crushed ice for 10 min, then removed by centrifugation
at 16,000 g × 10 min at 4°C. The supernatants containing
the extracted metabolites and internal standards in the
resulting 40:40:20 solvent mix of acetonitrile:methanol:
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at -80°C for LC-MS/MS (liquid chromatography-tandem
mass spectrometry) analysis.
LC-MS/MS analysis was performed by multiple reaction
monitoring (MRM) under Analyst v1.6.1 (AB SCIEX,
Framingham, MA, USA) software control in both negative
and positive mode with rapid polarity switching (50 ms).
Of the 673 metabolites targeted, 477 metabolites were
measured by scheduled MRM in the first injection, and
196 metabolites were measured by scanning MRM in a
second injection. Nitrogen was used for curtain gas (set to
30), collision gas (set to high), ion source gas 1 and 2 (set
to 35). The source temperature was 500°C. Spray voltage
was set to -4,500 V in negative mode and 5,500 V in posi-
tive mode. The values for Q1 and Q3 mass-to-charge ra-
tios (m/z), declustering potential (DP), entrance potential
(EP), collision energy (CE), and collision cell exit potential
(CXP) were determined and optimized for each MRM for
each metabolite. Ten microliters of extract were injected
by PAL CTC autosampler into a 250 × 2 mm, 5 μm Luna
NH2 aminopropyl HPLC column (Phenomenex, Torrance,
CA, USA) held at 25°C for chromatographic separation.
The mobile phase was solvent A: 95% water with 23.18
mM NH4OH (Sigma-Aldrich, St. Louis, MO, USA, Fluka
Cat# 17837-100ML), 20 mM formic acid (Sigma, Fluka
Cat# 09676-100ML) and 5% acetonitrile (pH 9.44); solvent
B: 100% acetonitrile. Separation was achieved using the
following gradient: 0 min 95% B, 3 min 95% B, 3.1 min
80% B, 6 min 80% B, 6.1 min 70% B, 10 min 70% B,
18 min 2% B, 27 min 0% B, 32 min 0% B, 33 min
100% B, 36.1 95% B, 40 min 95% B end. The flow rate
was 300 μL/min. All the samples were kept at 4°C during
analysis. The chromatographic peaks were identified using
MultiQuant (v3.0, AB SCIEX), confirmed by manual
inspection, and the peak areas integrated. The median
of the peak area of stable isotope internal standards was
calculated and used for the normalization of metabolites
concentration across the samples and batches. Prior to
multivariate and univariate analysis, the data were log-
transformed.
Metabolic pathway visualization in cytoscape
We constructed a rendering of mammalian intermediary
metabolism in Cytoscape v 3.1.1 (http://www.cytoscape.
org/). Pathways represented in the network for Fragile X
syndrome included the 20 metabolic pathways and the
58 metabolites that were altered by antipurinergic therapy
with suramin (VIP scores > 1.5). Nodes in the Cytoscape
network represent metabolites within the pathways and
have been colored according to the z-score. The z-score
was computed as the arithmetic difference between the
mean concentration of each metabolite in the KO-Sur
treatment group and the KO-Sal control group, divided by
the standard deviation in the controls. Node colors werearranged on a red-green color scale with green represent-
ing ≤-2.00 z-score, red representing ≥+2.00 z-score, and
with a zero (0) z-score represented as white. The sum of
the VIP scores of those metabolites with VIP scores >1.5
for each metabolic pathway is displayed next to the
pathway name.
Data analysis
Group means and standard error of the means (SEM)
are reported. Behavioral data were analyzed by two-
way ANOVA and one-way ANOVAs (GraphPad Prism
5.0d, GraphPad Software Inc., La Jolla, CA, USA, or
Stata/SE v12.1, StataCorp, College Station, TX, USA).
Pair-wise post hoc testing was performed by the
method of Tukey or Newman-Keuls. Significance was
set at P <0.05. Metabolomic data were log-transformed
and analyzed by multivariate partial least squares
discriminant analysis (PLSDA) in MetaboAnalyst
[25]. Metabolites with variable importance in projec-
tion (VIP) scores greater than 1.5 were considered
significant.
Results
Confirmation of Fragile X protein knockout
We confirmed the absence of Fragile X protein (FMRP)
expression in Fmr1 knockout mice, and its presence in
FVB and C57BL/6J controls by western blot analysis
before phenotyping the Fmr1 knockout animals used
in this study (Additional file 1: Figure S1).
Restoration of normal social behavior
Altered social behavior is a key measure of autism-like
features in mouse models of autism. In the Fragile X
knockout genetic model of autism, it has also proven to
be one of the most reproducible paradigms across differ-
ent studies reported in the literature [26]. We found that
Fmr1 null males showed a 26% reduction in social pref-
erence, as measured by the time spent interacting with a
stranger mouse compared to an inanimate object. There
was also a 35% reduction in social novelty, as measured
by the time spent interacting with a novel mouse com-
pared to a familiar mouse. This altered social behavior
was corrected by antipurinergic therapy with suramin
(Figure 1A-D).
Restoration of spontaneous alternation in the T-maze
Novelty preference is an innate feature of normal rodent
[27] and human [28] behavior, and a predictor of socialization
and communication growth in children with ASD [29].
The loss or suppression of novelty preference in children
with ASD is associated with the phenomenon known as
insistence on sameness [30]. We estimated preference for
novelty as spontaneous alternation behavior in the T-maze
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Figure 1 ASD-like symptoms were improved by antipurinergic therapy. (A) Social preference measured as percent time. Fmr1 knockouts
treated with saline showed significant deficits in social preference compared to wild-type controls (F(3,38) = 5.94, P = 0.002) and suramin corrected
this (P <0.05). (B) Social novelty measured as percent time. Fmr1 knockouts treated with saline also showed significant deficits in social novelty.
(F(3,38) = 3.49, P = 0.025) and suramin restored this (P <0.05). (C) Social preference as absolute time spent interacting socially. Fmr1 knockouts were
less social than wild-type controls and suramin treatment corrected this (cup F(1,76) = 56.5, P = 0.0001; cup x group F(3,76) = 3.55, P = 0.018).
(D) Social novelty as absolute time interacting with a novel mouse. Fmr1 knockouts showed decreased novelty preference and suramin improved
this (social stimulus main effect F(1,76) = 8.6; P = 0.004); social stimulus x group F(3,76) = 3.1, P = 0.032. Age 17 weeks; N = 9-12 per group for Social
Preference/Social Novelty test. (E) Restoration of spontaneous alternation in the T-maze. Suramin improved spontaneous alternation in the Fmr1
knockouts, but had not effect on FVB controls (F(3,41) = 16.6; P <0.0001). Age 13 weeks; N = 11-12 per group. (F) Restoration of normal marble
burying. Fmr1 knockouts treated with saline buried fewer marbles compared to controls (F(3,37) = 3.15; P = 0.037) and suramin corrected this
(P <0.05). Age 16 weeks; N = 9-12 per group. (G) Relative hypothermia in the Fragile X model and correction with suramin. Fmr1 knockout animals
treated with saline had core temperatures that were 0.5-0.7°C lower than wild-type FVB controls (F(3,41) = 10.45, P <0.0001). Suramin restored
normal body temperature in Fmr1 knockouts (P = 0.001). Age 15 weeks, N = 11-12 per group. Values are expressed as means +/- SEM.
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We did not use the food-motivated variation in our
study. We found that the Fmr1 null mice showed defi-
cient novelty preference as reflected by chance (near 50%)spontaneous alternation behavior. These deficits were
normalized by suramin treatment (Figure 1E). Fragile X
knockout mice were no different from controls in latency
to choice (data not shown).
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We measured marble burying as a measure of normal
rodent digging behavior. Marble burying has sometimes
been considered a measure of anxiety, however, compre-
hensive genetic and behavioral studies have shown that
marble burying is a normal mouse behavior that is genet-
ically determined [20]. We found that marble burying was
diminished 38% in Fragile X knockout mice. Suramin
improved this (KO-Sal v KO-Sur; Figure 1F).
Restoration of normal body temperature
Fmr1 knockout mice displayed relative hypothermia of
approximately 0.5°C to 0.7°C below the basal body
temperature of the FVB controls (Figure 1G). This relative
hypothermia was lost in stressed animals (data not shown).
The maternal immune activation (MIA) mouse model
showed a similar mild reduction in body temperature
[8]. Normal basal body temperature was restored by
antipurinergic therapy with suramin. Suramin had no
effect on the body temperature of control animals (WT-Sal
vs WT-Sur, Figure 1G).
Synaptosomal ultrastructure and protein expression
Our previous studies showed synaptic ultrastructural ab-
normalities in the MIA mouse model that were corrected
by antipurinergic therapy [8]. In that study, the animals
with ASD-like behaviors were found to have abnormal
synaptosomes containing an electron dense matrix and
brittle or fragile and hypomorphic post-synaptic densities.
In the present study of the Fragile X model, saline-treated
Fmr1 knockout mice had cerebral synaptosomes that also
contained an electron dense matrix (Figure 2A, marked
with an asterisk), and fragile, hypomorphic post-synaptic
densities (Figure 2A, marked with an arrow). Normal
appearing synaptosomes were also found in the Fmr1Figure 2 Cerebral synaptosome structural abnormalities were
improved by antipurinergic therapy. (A) Fragile X knockout
model treated with saline (KO-Saline). Note the increased electron
density (dark staining) of the synaptosomal matrix (*) and the
hypomorphic (thin) margins of the post-synaptic density (indicated
by the arrow). Age 25 weeks, N = 3 per group. Scale bar = 200 nm.
(B) Fragile X knockout model treated with suramin (KO-Suramin).
Note the normal appearing, electron lucent synaptosomal matrix (*)
and the thicker margins of the post-synaptic density (indicated by
the arrow). Age 25 weeks, N = 3 per group. Scale bar = 200 nm.knockout animals, reflecting the well-known hetero-
geneity in synaptic maturation and morphology in this
model. Suramin-treated mice had more cerebral synap-
tosomes that were near-normal in appearance, with an
electron lucent matrix (Figure 2B, marked with an as-
terisk), and normal appearing post-synaptic densities
(Figure 2B, marked with an arrow). We did not investi-
gate dendritic spine densities in this study.
Cerebral synaptosomal protein analysis
We found that 17 of 54 proteins we interrogated in cere-
bral synaptosomes (see Additional file 1: Table S1) were
changed by antipurinergic therapy with suramin in the
Fragile X model (Figures 3 and 4; KO-Sur vs. KO-Sal).
As a treatment study, we focused on the effect of suramin
in the Fmr1 knockout mice only. The current study did
not compare knockout brain protein levels to littermate
FVB controls (see Methods).
Synaptosomal PI3K/AKT/GSK3β pathway
The PI3/AKT/GSK3β pathway is pathologically elevated
in the Fragile X model [32]. Suramin inhibited this path-
way at several points. Suramin decreased the expression
of PI3 Kinase and AKT, and increased the inhibitory
phosphorylation of the PI3K/AKT pathway protein glyco-
gen synthase kinase 3β (pGSK3βSer9) by 47%. Suramin in-
creased the phosphorylation of p70 S6 kinase (pS6KThr389)
by 46% (Figures 3 and 4A-F). Phosphorylated p70 S6KThr389
is a negative regulator of insulin receptor substrate 1
(IRS1), and serves to oppose insulin stimulated cell
growth, PI3K, and mTORC1 signaling [33]. We did not
find a corresponding change in mTOR expression or
phosphorylation in cerebral synaptosomes of the Fragile X
model (Additional file 1: Table S1).
Synaptosomal adenomatous polyposis coli (APC)
expression
APC is a tumor suppressor protein that is increased in
the Fragile X knockout model [34]. APC forms a complex
with, and is phosphorylated by, active GSK3β to inhibit
microtubule assembly during undifferentiated cell growth
of neuronal progenitors [35]. Suramin treatment returned
total APC protein to control levels by decreasing expres-
sion by 29% (Figure 4G).
Synaptosomal purinergic receptors and the IP3R1 calcium
channel
In earlier studies we showed the chronic hyperpurinergia
associated with the MIA mouse model resulted in down-
regulated expression of the P2Y2 receptor. Suramin treat-
ment in the MIA model increased P2Y2 expression to
normal levels [8]. In the Fragile X mouse model, suramin
treatment increased the expression of the P2Y1 recep-
tor 32%, and decreased P2X3 receptor expression 18%
Figure 3 Western analysis of cerebral synaptosomal proteins changed by suramin treatment. Seventeen of 54 interrogated proteins were
found to be changed by suramin treatment measured at 25 weeks of age. Post-synaptic density protein 95 kD (PSD95) was not influenced by
suramin treatment and was used as a loading control. Protein expression data quantified by densitometry.
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(Additional file 1: Table S1). P2Y1 signaling is known
to inhibit IP3 gated calcium release from the endoplas-
mic reticulum [36]. We found that suramin treatment
was associated with a 101% increase in IP3R1 expres-
sion (Figure 4J).
Synaptosomal AMPA receptor (GluR1) expression
AMPA receptor (GluR1) mRNA transcription, translation,
and receptor recycling are known to be pathologically
dysregulated in the Fragile X model [37]. In the lateral
amygdala, the Fragile X knockout results in enhanced
internalization and increased internalized receptor pools,
with decreased surface expression, such that the total
mass of the AMPA receptor is unchanged from controls
[38]. Suramin treatment decreased the overall expression
of the ionotropic GluR1 in cerebral synaptosomes by 15%
(Figure 4K). However, these methods were unable to dis-
tinguish between surface and internalized pools of AMPA
receptors. Suramin had no effect on metabotropic glutam-
ate receptor mGluR5 expression in this model (Additional
file 1: Table S1).
Synaptosomal cannabinoid receptor expression
Cannabinoid signaling is pathologically increased in the
Fmr1 knockout model [39]. Suramin treatment decreased
brain CB1 receptor expression 16% (Figure 4L). This is
consistent with recent data that have shown signaling to
be sharply increased in response to brain injury [40].
Pharmacologic blockade with the CB1R antagonist rimo-
nabant has been shown to improve several symptoms in
the Fragile X model [41]. CB2 expression is increased inthe peripheral blood monocytes of children with autism
spectrum disorders [42]. However, CB2 receptor expres-
sion in the brain synaptosomes of the Fragile X model was
unchanged (Additional file 1: Table S1).
Synaptosomal PPARβ/δ expression
PPARβ (also known as PPARδ) is a widely expressed
transcriptional co-activator that is correlated with the
aerobic and bioenergetic capacity in a variety of tissue
types [43]. Suramin treatment increased the expression
of PPARβ/δ in purified brain synaptosomes by 34%
(Figure 4M). Suramin treatment had no effect on syn-
aptosomal PPARα (Additional file 1: Table S1).
Synaptosomal cholesterol and bile acid regulatory
proteins
Antipurinergic therapy with suramin increased three
key proteins involved in sterol and bile acid synthesis.
7-dehydrocholesterol reductase (7DHCR) was increased
by 24%, cholesterol 7α-hydroxylase (CYP7A1) by 37%,
and the steroidogenic acute regulatory (StAR) protein
by 150% (Figure 4N-P) above saline treated control levels.
The function of bile salts in the brain is unknown, although
their neuroprotective effects have been shown in several
models [44,45].
Synaptosomal complement C1q and TDP43
Recent studies have revealed an important role for com-
plement proteins in tagging synapses during inflammation
and remodeling [46]. Activated complement proteins have
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Figure 4 Cerebral synaptosomal proteins changed by antipurinergic therapy with suramin. (A) Phosphoinositol trisphosphate kinase
(PI3K). (B) Akt (protein kinase B). (C) Serine 9 phosphorylation of glycogen synthase kinase (pGSK3β). (D) Phosphorylation ratio of glycogen synthase
kinase 3β (pGSK3β/GSK3β). (E) Phosphorylated of ribosomal protein S6 Kinase (pS6K). (F) Phosphorylation ratio of pS6K/S6K. (G) Adenomatous
polyposis coli (APC). (H) Purinergic receptor P2X3 (P2X3R). (I) Purinergic receptor P2Y1 (P2Y1R). (J) Inositol trisphosphate receptor (IP3R). (K) Glutamate
receptor 1 (GluR1, also known as the AMPA receptor). (L) Cannabinoid receptor 1 (CB1). (M) Peroxisome proliferator activated receptor β
(PPARβ, also known as PPARδ). (N) 7-Dehydrocholesterol dehydrogenase (7-DHCR). (O) Cholesterol 7α-hydroxylase (CYP7A1). (P) Steroidogenic
acute response protein (StAR). (Q) Activated complement protein C1q (C1qA). (R) TAR DNA binding protein 43 (TDP43). (S) Amyloid-β precursor
protein (APP). Age = 25 weeks, N = 5 per group. Values are expressed as means +/- SEM.
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http://www.molecularautism.com/content/6/1/1We found that suramin decreased synaptosomal C1qA by
24% (Figure 4Q).
Tar-DNA binding protein 43 (TDP43) is a single-strand
DNA and RNA binding protein that disturbs mitochon-
drial transport and function under conditions of cellstress [48]. Mutations in TDP43 are associated with genetic
forms of amyotrophic lateral sclerosis (ALS) [49]. Wild-
type TDP43 protein is a component of the tau and
α-synuclein inclusion bodies found in Alzheimer’s and
Parkinson’s disease and plays a role in RNA homeostasis
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tions to the role of the Fmr1 gene in RNA homeostasis
prompted us to investigate TDP43 in the Fragile X model.
We found that suramin treatment decreased synaptosomal
TDP43 by 27% (Figure 4R).
Synaptosomal amyloid-β precursor protein expression
Amyloid-β precursor protein (APP) expression is upregu-
lated in the brain of subjects with ASD [51]. A number of
recent papers have identified the upregulation of gene net-
works in ASD [51] and inborn errors of purine metabolism
[52] that were formerly thought to be specific for Alzhei-
mer’s and other neurodegenerative disorders. We found that
antipurinergic therapy with suramin decreased synapto-
somal APP levels by 23% in the Fragile X model (Figure 4S).
Synaptosomal protein pertinent negatives
We interrogated the effect of suramin on several add-
itional proteins that were found to be dysregulated in
the MIA mouse model [8]. We found no effect of sura-
min in the Fragile X model on ERK 1 and 2, or its phos-
phorylation, CAMKII or its phosphorylation, nicotinic
acetylcholine receptor alpha 7 subunit (nAchRα7) ex-
pression, or the expression of the purinergic receptors
P2Y2 and P2X7 (Additional file 1: Table S1). These data
show that the detailed molecular effects of antipurinergicFigure 5 Antipurinergic therapy improved the widespread metabolom
plasma metabolites from 60 biochemical pathways were measured by liqu
analyzed by partial least squares discriminant analysis (PLSDA). The three to
respectively. Suramin treatment shifted metabolism in the direction of wildtherapy with suramin are different in different genetic
backgrounds and different mechanistic models of autism
spectrum disorders. However, the efficacy in restoring nor-
mal behavior and brain synaptic morphology cuts across
models. These data support the novel conclusion that anti-
purinergic therapy is operating by a metabolic mechanism
that is common to, and underlies, both the environmental
MIA, and the genetic Fragile X models of ASD.Metabolomic response to suramin treatment
We analyzed the metabolomic effects in plasma of Fragile
X mice after weekly treatment with suramin or saline. We
measured 673 metabolites from 60 pathways by mass spec-
trometry (Additional file 1: Table S2), analyzed the data by
partial least squares discriminant analysis (PLSDA), and
visualized the results by projection in three dimensions
(Figure 5), and ranked by the metabolic changes by vari-
able importance in projection (VIP) scores (Figure 6). This
analysis focused on the rank order of importance. Larger
sample sizes, usually ≥15 animals per group, are required
for more comprehensive metabolomic statistical analysis
[53]. We found that suramin produced pharmacometabo-
lomic changes in one-third of the biochemical pathways
interrogated (20 of 60 pathways). These are summarized
below.ic abnormalities in the Fragile X mouse model. A total of 673
id chromatography tandem mass spectrometry (LC-MS/MS) and
p multivariate components were then plotted on x, y, and z-axes,
-type controls. Age 25 weeks, N = 9-11 per group.
Figure 6 Metabolites and pathways associated with suramin treatment in the Fragile X model. The top 30 most discriminating
metabolites and their biochemical pathways ranked by variable importance in projection (VIP) scores. See Additional file 1: Table S3 for a
complete list of the top 58 discriminating metabolites. VIP scores ≥1.5 were considered statistically significant. Age 25 weeks, N = 9-11 per group.
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The top 11 of 20 discriminating metabolic pathways were
represented by two or more metabolites and contributed
89% of the most discriminating metabolites in the Fragile
X mouse model treated with suramin (Table 1). These
pathways were: purines (20%), fatty acid oxidation (12%),
eicosanoids (11%), gangliosides (10%), phospholipids (9%),
sphingolipids (8%), microbiome (5%), SAM/SAH gluta-
thione (5%), NAD+ metabolism (4%), glycolysis (3%),
and cholesterol metabolism (2%) (Table 1).
A simplified map of metabolism is illustrated in the
form of 26 major biochemical pathways in Figure 7. This
figure shows the effect of suramin treatment on each me-
tabolite as measured in the plasma. The magnitude of the
pharmacometabolomic effect is quantified as the z-score
for nearly 500 metabolites. Inspection of this figure leads
to several conclusions. First, 1-carbon folate and Krebs
cycle metabolism are dominated by red shading, indicat-
ing a general increase in methylation pathways, and mito-
chondrial oxidative phosphorylation. Next, there was a
generalized increase in intermediates of the SAM/SAH
and glutathione metabolism. Purine metabolism showed a
mixture of upregulated precursors of adenine nucleo-
tides and downregulated inosine and guanosine precur-
sors. There was a generalized increase in gangliosides,
phospholipids, and cholesterol metabolites needed formyelin and cell membrane synthesis. Finally, there
was a generalized decrease in nine of nine acyl-
carnitine species. Acyl-carnitines accumulate when fatty
acid oxidation is impaired, and decline when normal mito-
chondrial fatty acid oxidation is restored. Each of these
pathways is a known feature of the cell danger response
(CDR) [54].
Lipid metabolism
Disturbances in lipid metabolism were a prominent fea-
ture of the Fragile X mouse model (Additional file 1:
Figures S3A-D), and its response to treatment (Table 1,
Figure 7). Treatment with suramin produced concerted
effects in eight different classes of lipids that collectively
explained 54% of the top ranked metabolites identified
by multivariate analysis. In rank order of importance
these were: fatty acid metabolism (12%), eicosanoid me-
tabolism (11%), ganglioside metabolism (10%), phospho-
lipid metabolism (9%), sphingolipids (8%), cholesterol/
sterols (2%), cardiolipin (1%), and bile acids (1%) (Table 1).
Suramin also had a significant impact on lipid metabolism
in the MIA model. Four of the top six metabolic pathways
were lipids, explaining 30% of the top ranked VIP scores.
In rank order of importance the lipid pathways in the
MIA model were: phospholipids (8%), bile acids (8%),
sphingolipids (7%), and cholesterol/sterols (7%) [9].
Table 1 Biochemical pathways with metabolites changed by antipurinergic therapy in the Fragile X mouse model




























1 Purine metabolism 41 0.061 3.54 5 1.41 27.2 20.0% 4/5 Decreased
2 Fatty acid oxidation
and synthesis
39 0.057 3.37 9 2.67 16.8 12.4% 9/9 Decreased
3 Eicosanoid and
resolvin metabolism
36 0.053 3.11 6 1.93 14.7 10.8% 4/6 Increased
4 Ganglioside
metabolism
12 0.018 1.04 6 5.79 13.4 9.8% 6/6 Increased
5 Phospholipid
metabolism
115 0.18 9.93 6 0.60 11.5 8.5% 6/6 Increased
6 Sphingolipid
metabolism
72 0.105 6.21 5 0.80 11.1 8.2% 3/5 Decreased
7 Microbiome
metabolism
33 0.047 2.85 3 1.05 6.7 4.9% 2/3 Decreased
8 SAM, SAH, methionine,
cysteine, glutathione
metabolism




8 0.012 0.69 2 2.90 5.2 3.8% 1/2 Increased
10 Glycolysis and
gluconeogenesis








6 0.009 0.52 1 1.93 2.1 1.5% Increased
13 Cardiolipin
metabolism
12 0.018 1.04 1 0.97 2.0 1.4% Decreased
14 Bile salt metabolism 8 0.012 0.69 1 1.45 1.8 1.3% Increased
15 Branch chain amino
acid metabolism





4 0.006 0.35 1 2.90 1.7 1.2% Increased
17 Pyrimidine metabolism 31 0.051 2.68 1 0.37 1.6 1.1% Decreased




5 0.007 0.43 1 2.32 1.5 1.1% Increased
20 Pentose phosphate,
gluconate metabolism
11 0.016 0.95 1 1.05 1.5 1.1% Increased
20 of 60 pathways
dysregulated
532 (0.79 x 673) 79% (532/673) 46 (0.79 x 58) 58 136.0 100% 33/58 Increased
Pathways were ranked by their impact measured by summed VIP (ΣVIP; variable importance in projection) scores. A total of 58 metabolites were found to discriminate
suramin-treated and saline-treated Fragile X knockout groups by multivariate partial least squares discriminant analysis (PLSDA). Significant metabolites had VIP scores
of ≥1.5. Twenty (33%) of the 60 pathways interrogated had at least one metabolite with VIP scores ≥1.5. The total impact of these 58 metabolites corresponded to a
summed VIP score of 136. The fractional impact of each pathway is quantified as the percent of the summed VIP score and displayed in the final column on the right in
the table. Antipurinergic therapy with suramin not only corrected purine metabolism, but also produced changes in 19 other pathways associated with multi-system
improvements in ASD-like symptoms.
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Figure 7 (See legend on next page.)
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Figure 7 Cytoscape visualization of the metabolic pathways altered by antipurinergic therapy in the Fragile X mouse model. Twenty-six
of the 60 biochemical pathways interrogated in our metabolomic analysis are illustrated. See Additional file 1: Tables S2 and S3 for complete
listing of pathways and discriminating metabolites, respectively. The fractional contribution of each of the top 20 pathways altered by suramin
treatment is indicated as a percentage of the total variable importance in projection (VIP) score in the black circles. Purine metabolism contributed
20% of the top ranked VIP scores, followed by fatty acid oxidation (12%), eicosanoids (11%), gangliosides (10%), phospholipids (9%), and 15
other biochemical pathways as indicated. Smaller circles indicate the metabolites in each pathway, quantified by z-score. Metabolites in red
were increased. Metabolites in green were decreased by treatment with suramin. Age 25 weeks, N = 9-11 per group.
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models
We compared the 20 pathways found to be altered in the
Fragile X model (Table 1) to the 18 metabolic pathways
that were altered in the maternal immune activation
(MIA) model [8]. A Venn diagram of this comparison
revealed 11 pathways that were shared between these
two models (Figure 8). These were purines, the micro-
biome, phospholipid, sphingolipid, cholesterol, bile acids,
glycolysis, the Krebs cycle, NAD+, pyrimidines, and S-
adenosylmethionine (SAM), S-adenosyl-homocysteine
(SAH), and glutathione (GSH) metabolism.
Discussion
The Fragile X mouse model is one of the most com-
monly studied genetic mouse models of ASDs. UsingFigure 8 Metabolic pathways shared by the MIA and Fragile X mouse
identified 20 biochemical pathways associated with symptom improvemen
shared with human ASD, and 11 were shared with the maternal immune a
human ASD were: purines, microbiome, sphingolipids, phophoslipids, choleste
methionine (SAM)/S-adenosylhomocysteine (SAH)/glutathione (GSH), fatty aci
oxide (ROS/NO), branched chain amino acids, propionate metabolism and pro
metabolism. Bile acids were common to both the Fragile X and MIA models,this genetic model, we found that antipurinergic therapy
(APT) with suramin improved the behavioral, metabolic,
and the synaptic structural abnormalities. We previously
showed that the ASD-like symptoms of the maternal im-
mune activation (MIA) mouse model were also im-
proved by antipurinergic therapy [8]. Regardless of the
model - whether ‘environmental’ like the MIA model, or
‘genetic’ like the Fragile X knockout model - antipuriner-
gic therapy with suramin corrected the abnormalities
that characterized each model. Our results support the
novel conclusion that antipurinergic therapy is operating
by a mechanism that lies close to the root cause of the
core behaviors and development in both the environ-
mental MIA, and the genetic Fragile X models of ASD.
This mechanism appears to be traceable to mitochondria
and regulated by purinergic signaling.models and human ASD. Comprehensive metabolomic analysis
ts in the Fragile X (Fmr1 knockout) model. Seventeen pathways were
ctivation (MIA) model of ASD. The 17 metabolic pathways shared with
rol/sterols, glycolysis, Krebs cycle, vitamin B3-NAD+, pyrimidines, S-adenosyl
d oxidation, eicosanoids, gangliosides, reactive oxygen species and nitric
piogenic amino acids (Ile, Val, Thr, and Met), and vitamin B6-pyridoxine
but have not yet been studied in human autism.
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conclusions. The Fragile X knockout mouse model is an
imperfect model of human Fragile X syndrome. Human
Fragile X syndrome is not the result of knockout of the
gene, but rather an expansion of a CGG triplet repeat in
the 5’ untranslated region of the gene, and variable phe-
notypes have been reported in the mouse model [26].
As with many syndromic, single gene disorders, human
Fragile X syndrome itself is an imperfect model of non-
syndromic ASDs. At least 40% of the boys [55], and over
90% of the girls [56] with Fragile X syndrome do not
meet the diagnostic criteria for ASD. We studied the
most commonly reported genotype of the Fmr1 knock-
out mouse model, which was backcrossed for 11 genera-
tions on the genetic background of the FVB strain of
laboratory mouse. We compared the behavioral features
of this Fmr1 knockout to the FVB control strain. A po-
tential weakness of our study is that Fmr1 knockout and
FVB control strains are not littermate controls raised by
the same mothers. Some behavioral differences might
be the result of differences in maternal genotype and
rearing. However, the point of our study was not to re-
confirm the known behavioral and molecular features of
Fragile X model, but rather to ask the question, ‘Are the
abnormalities treatable with antipurinergic therapy (APT)?’
Our data suggest that they were.
Other treatments have also been successful in mitigat-
ing the symptoms of the Fragile X mouse by addressing
specific neurotransmitter or synaptic defects. These have
included drug inhibition of glutamatergic signaling with
mGluR5 inhibitors [57], inhibition of endocannabinoid
signaling [41], and genetic inhibition of amyloid β pre-
cursor protein (APP) [58]. A number of metabolic ther-
apies have also been successful. These have included
acetyl-L-carnitine [59], omega 3 fatty acid therapy [60],
and inhibition of the metabolic control enzyme glycogen
synthase kinase 3β (GSK3β) [32]. Remarkably, we found
that antipurinergic therapy addressed each of these ab-
normalities with a single intervention. Minocycline has
also shown benefit in both human Fragile X syndrome
[61] and mouse models [62]. Interestingly, many of the
neuroprotective and anti-inflammatory effects of mino-
cycline have been traced to its actions on mitochondrial
function [63,64], and may also act to decrease hyperpuri-
nergia by moderating mitochondrial ATP synthesis.
Purine metabolism was the most discriminating single
metabolic pathway in the Fragile X mouse model treated
with suramin, contributing 20% of the top ranked metabo-
lites identified by multivariate analysis (Table 1, Figure 7).
An important pharmacologic mechanism of action of
suramin is as a competitive antagonist of extracellular
ATP and other nucleotides, acting at purinergic receptors
[9,65]. Suramin also has nearly 30 other actions [18]. Our
metabolomic data show that the major functional impactof suramin in the Fragile X mouse model was on purine
metabolism (Table 1). Purinergic signaling abnormalities
linked to autism-like behaviors are not restricted to animal
models. Several inborn errors in purine [15] and pyrimi-
dine metabolism [14] are well known to be associated with
autism-like behaviors [9]. In addition, abnormalities in
purine metabolism leading to hyperuricosuria in 20% of
children with non-syndromic autism have been described
[66]. The specific link between purine metabolism in ASD
and purinergic signaling was first made in 2012 [67], and
tested in the MIA mouse model in 2013 [8]. Interestingly,
brain purinergic signaling was recently identified as one of
the top gene expression pathways correlated with abnor-
mal behaviors in children with ASD [68].
We next compared the metabolomic results for both
the maternal immune activation (MIA) [9] and Fragile X
mouse models of ASD (Figure 8). We found 11 meta-
bolic pathways that were common to both models. These
were purines, microbiome, phospholipids, sphingolipids/
gangliosides, cholesterol/sterol, bile acids, glycolysis,
mitochondrial Krebs cycle, NAD+/H, pyrimidines, and
S-adenosylmethionine/homocysteine/glutathione (SAM/
SAH/GSH) metabolism. Seventeen of the 20 metabolic
pathway disturbances found in the Fragile X mouse
model have been described in human ASD. These in-
clude purine metabolism [15,66], fatty acid oxidation
[69], microbiome [70,71], phospholipid [72], eicosanoid
[73-75], cholesterol/sterol [76], sphingolipids and gan-
gliosides [77,78], glycolysis, Krebs cycle and mitochon-
drial metabolism [79-81], nitric oxide and reactive
oxygen metabolism [82], branched chain amino acids
[83], propionate and propiogenic amino acid metabol-
ism (IVTM; Ile, Val, Thr, Met) [84], pyrimidines [14],
SAM/SAH/glutathione [85], vitamin B3-NAD+ metabol-
ism [86], and vitamin B6-pyridoxine metabolism [87]. We
found plasma cardiolipin was therapeutically down-
regulated by suramin. Although elevations in plasma
cardiolipin species have not yet been reported in children
with autism, anti-cardiolipin antibodies have [88].
The upregulation of glycolysis and downregulation of
mitochondrial Krebs cycle seen in the Fragile X model
of ASD are a direct consequence of the regulated decrease
in mitochondrial oxidative phosphorylation (oxphos). This
was corrected by suramin (Figure 7). The conditions of in-
creased substrate supply and decreased utilization, create
a poised state of mitochondrial underfunction associated
with increased reserve capacity. When basal mitochon-
drial oxygen consumption is decreased, cellular heat pro-
duction from mitochondria is reduced. This can lead to a
decrease in basal body temperature. We observed a 0.7°C
decrease in basal body temperature in the Fragile X mice
(Figure 1G). A similar decrease was seen in the MIA
mouse model [8]. A poised increase in mitochondrial re-
serve capacity can also produce primed mitochondria with
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cases, this is manifest as a large increase in mitochondrial
reactive oxygen species (ROS) production. Interestingly,
an increase in mitochondrial reserve capacity and increased
ROS production under stress has been documented in 32%
of lymphocytoblastoid cell lines (8/25 = 32%; 95% CI
15-54%) derived from children with ASD [79]. When
an explosive discharge of mitochondrial ROS occurs
transiently, uncoupling can result, leading to a large in-
crease in mitochondrial heat production and high fevers.
Superfevers of 104.5° to 105.5°F have been described in
occasional patients with Fragile X during infectious illness
(personal communication, Randi J. Hagerman).
When cellular resources are redirected away from work,
changes in activity-dependent gene expression result in a
reduction in unused proteins [89]. With time these under-
utilized cells lose the capacity for specific kinds of work
and can enter a physiologically-induced hypometabolic
state that protects the cell from harsh extracellular condi-
tions and promotes cellular persistence. This state shares
metabolic similarities to the dauer state in C. elegans [90],
embryonic diapause in mammals [91], plant seed develop-
ment [92], and stem cells that can be recruited back into
cycle after stasis or injury [93]. This latter point suggests
that tissues and organs can exist as shifting mosaics of
fully active cells, and hypometabolic cells that can be
called into action, depending on environmental condi-
tions. In each case, mitochondrial fatty acid oxidation is
decreased to facilitate intracellular lipid accumulation
needed for persistence metabolism. Fatty acid oxidation
was the second most discriminating pathway in the Fragile
X mouse model treated with suramin, contributing 12%
of the top ranked metabolites identified by multivariate
analysis (Table 1, Figure 7). Several acyl-carnitine spe-
cies were elevated (Table 1, Figure 6). This is a hallmark
of diminished mitochondrial fatty acid oxidation [94].
Similar elevations of acyl-carnitines have been reported
in 17% of human ASD [69]. Suramin treatment decreased
plasma acyl-carnitine levels in the Fragile X model
(Figures 6 and 7).
Eicosanoid metabolism was the third most discrimin-
ating metabolic pathway in the Fragile X mouse model
treated with suramin, contributing 11% of the top
ranked metabolites identified by multivariate analysis
(Table 1, Figure 7). Eicosanoid metabolism plays a cru-
cial role in regulating the balance of inflammation and
anti-inflammation after acute injury, during chronic
disease [95,96], and in the antiviral and antibacterial
innate immune response [97]. Upregulated lipoxygen-
ase activity in the Fragile X mouse model was recently
predicted on the basis of FMRP binding to lipoxygenase
mRNA, and disinhibition in the knockout, in a medical
hypothesis paper by Beaulieu [75]. The predicted increase
in hydroxyeicosatetraenoic acid (HETE) species wouldsupport mGluR5-mediated long-term depression (LTD)
[98], which is a well-known problem in Fragile X syn-
drome [99]. We found that suramin treatment increased
two epoxyeicosatrienoic acids (EETs), and decreased a
stable metabolite of platelet thromboxane A2 (TXA2),
11-dehydro-thromboxane B2 (Figures 6 and 7). The in-
crease in EETs has several physiologic benefits. These
include a decrease in ER stress [100], an increase in
AMPK activation, and an increase in autophagy [101].
The increase in EETs and decrease in TXA2 were con-
sistent with the anti-inflammatory action of antipuriner-
gic therapy with suramin.
Considered as a coordinated system, these data show
that the metabolic disturbances in the mouse models of
ASD are similar to those found in human ASD (Figure 8).
The data provide strong support for the biochemical valid-
ity of both the MIA and Fragile X mouse models. In
addition, the metabolomics data revealed for the first time
the surprising observation that the environmental MIA
and the genetic Fragile X mouse models, and human
ASD, all shared disturbances in biochemical pathways
previously identified as features of the evolutionarily
conserved cell danger response (CDR) (Figure 8) [54].
We found that in the mouse models, both the ASD-like
symptoms and the biochemical features of the CDR
were corrected by antipurinergic therapy with suramin.
Purinergic signaling begins with the regulated release
of purine nucleotides like ATP, or pyrimidines like UTP,
through channels in the cell membrane for autocrine
and paracrine signaling, and by vesicular fusion during
neurotransmission [102,103]. Purinergic (P2X and P2Y)
receptors bind to extracellular ATP and other nucleo-
tides as a means of sensing cellular health and danger
[54,104]. In this usage, the word ‘danger’ is not an an-
thropomorphic construct. Danger has a chemical meaning
in cells that equates to metabolic mismatches between
substrate/product ratios and the gene-coded and allosteri-
cally regulated equilibrium constant (Keq) of each relevant
enzyme located in mitochondria, and the conductances of
transporters in and out of the organelles [105]. These mis-
matches are coupled to mitochondrial oxygen consump-
tion, electron flow, redox, and oxidative phosphorylation,
and produce a sequence of graded metabolic responses
that alter DNA methylation [106], histone modifications
[107], and lead to new cellular states of gene expression
and function [108]. In most differentiated cells, mitochon-
dria make 90% of the ATP, and process 90% of the carbon
skeletons and activated sulfur intermediates used to create
the building blocks for cell growth, function, detoxifica-
tion, and repair. Mitochondria serve as the cellular trans-
lators of real-time metabolic information, integrating it
with the genetics of the cell, and providing feedback in the
form of retrograde signals to the nucleus [109] used to
change gene expression.
Table 2 Summary of antipurinergic therapy results in the Fragile X mouse model of autism spectrum disorders
Feature Abnormality in Fragile X males vs. FVB
controls
Response to antipurinergic therapy
Social preference Decreased Normalized (P <0.05)
Social novelty Decreased Normalized (P <0.05)
T-maze spontaneous alternation Decreased Normalized (P <0.001)
Marble burying Decreased Normalized (P <0.05)
Core body temperature Decreased Normalized (P <0.001)
Acoustic startle Decreased [sic] Unchanged (P = ns)
Metabolomics (60 pathways measured) 20 of 60 pathways disturbed 33 metabolites increased and 25 decreased of 58
changed
Synaptosomal structure by electron
microscopy
Fragile and malformed post-synaptic densities;
Accumulation of electron dense matrix material
Improved
Synaptosomal proteins (54 interrogated) N/A 17 proteins were changed (for example, decreased
PI3/GSK3β, GluR1, C1q, and APP; increased PPARβ/δ)
Locomotor activity - total distance (hyperactivity),
center exploration, holepokes, rearing
None N/A
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on the cell surface it is participating in what we call a
‘long-path’ retrograde signaling circuit from mitochon-
dria to the unstirred water layer on the cell surface, to
neighboring cells, or back through autologous cell mem-
brane G-protein coupled receptors and ion channels, to
calcium signaling, back to mitochondria and other cellular
compartments, and ultimately to the nucleus, changing
gene expression. This extracellular purinergic signaling
circuit is well known to regulate innate immunity, oxida-
tive stress and shielding [110], inflammation, and cytokine
production [104], sensory perception [111], in addition to
sleep, cognition [112], and the autonomic nervous system
[113]. Intracellular adenine nucleotides like NAD+/H,
NADP+/H, cyclic-ADP-ribose (cADPR), and nicotinic acid
adenine dinucleotide phosphate (NAADP) are also trace-
able to mitochondria, are interconverted by the enzyme
CD38 [114], and play important roles in a ‘short-path’
retrograde signaling circuit that regulates redox, calcium
release, sodium and potassium channels [115], synaptic
long-term depression [116], autophagy [117], defense
against intracellular pathogens [118], and social behavior
by modulating oxytocin secretion [119]. These studies
underscore the surprising role of extracellular and intra-
cellular purines in regulating a diverse array of biological
phenomena, ranging from innate immunity and cellular
defense, to sleep, cognition, behavior, perception, affect,
memory, and learning.
Although our results showing the correction of ASD-
like behaviors, and improvements in metabolism and
brain synaptic abnormalities in the Fragile X mouse
model are encouraging, there are several caveats that
must be considered before extending the results to
humans. First, while the Fragile X mouse model cap-
tures several features of ASD, no animal model can fullycapture the complexities of human behavior. Second,
suramin is a poor drug choice for chronic use because
of potentially toxic side effects that can occur with pro-
longed treatment [120]. Third, human forms of ASD
may occur by mechanisms not captured by the Fragile X
model. Mechanisms that do not involve the pathological
persistence of the cell danger response (CDR) [54] may
not be amenable to antipurinergic therapy. Newer, safer,
more selective antipurinergic drugs, and human clinical
trials will be necessary to answer these questions.Conclusions
The data reported in this study show that the efficacy of
antipurinergic therapy cuts across disease models of
ASD. Both the environmental MIA [8,9] and the genetic
Fragile X models (Figures 1, 2, 3, 4, 5, 6, 7, 8, Tables 1
and 2) responded with complete, or near-complete, reso-
lution of symptoms, even when treatment was not begun
until adolescence, or adulthood. The data support the hy-
pothesis that disturbances in purinergic signaling may be a
common denominator and effective therapeutic target in
both the environmental MIA and genetic Fragile X mouse
models of autism spectrum disorders.Additional file
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